PR Newswire: news distribution, targeting and monitoring
 

FDA Public Health Alert: Que She Weight Loss Capsules Contain Potentially Harmful Ingredients

 

SILVER SPRING, Md., July 8  /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned that Que She, marketed as an herbal weight loss supplement, contains active pharmaceutical ingredients not listed on the product label that could harm consumers, especially those with cardiovascular conditions.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

People who have purchased Que She should stop taking the product immediately and consult a health care professional.

Que She, advertised as "Slimming Factor Capsule" and as "an all-natural blend of Chinese herbs," has been widely distributed on Internet sites such as the Bouncing Bear Botanicals website, and at retail outlets, including Sacred Journey in Lawrence, Kan.

An FDA analysis of Que She found that it contains:

  • fenfluraminea stimulant drug withdrawn from the U.S. market in 1997 after studies demonstrated that it caused serious heart valve damage
  • propranolol – a prescription beta blocker drug that can pose a risk to people with bronchial asthma and certain heart conditions
  • sibutramine – a controlled substance and prescription weight loss drug, sibutramine was the subject of a recent study whose preliminary findings showed an association between sibutramine use and increased risk of heart attack and stroke in patients who have a history of heart disease
  • ephedrinea stimulant drug that is legally marketed over-the-counter for temporary relief of asthma but can pose a risk to people with certain cardiovascular conditions

These active pharmaceutical ingredients also may interact with other medications and result in a serious adverse event.

Consumers and health care professionals are encouraged to report adverse events related to the use of Que She to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: online at www.fda.gov/MedWatch/report.htm; by phone at 800-FDA-1088 (800-332-1088); or, by returning FDA form 3500, available on the MedWatch "Download Forms" page by mail to the address on the pre-addressed form or by fax at 800-FDA-0178.

Media Inquiries: Elaine Gansz Bobo, 301-796-7567, elaine.bobo@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA



SOURCE U.S. Food and Drug Administration

Back to top

RELATED LINKS
http://www.fda.gov/

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

Featured Video

 
  • Print
  • Email
  •   RSS
  • Share it 
  • Blog it 
  • Blog Search 

More in These Categories

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Free Investing Newsletter from Investor Uprising!

Learn to navigate the world's financial system and profit from leading companies.  


Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All The Glitters: The Ultimate Gold Report".

Advanced Search
Search
  
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire